Transpek Industry Ltd Q3 FY2023 Concall Summary

Key Takeaways

• Steady demand, permission-constrained: Nine-month revenue grew 32% YoY on steady volumes and new products, but Q3 growth moderated to just 5% YoY, and management flagged that permission limits cap near-term output.
• New products are the growth engine: Five products introduced in 9M FY23, two more in the pipeline, and a 15–17 product development funnel targeting pharma, polymers, and agrochemicals across multiple regions.
• Capacity expansion is on the drawing board: A new multi-product Friedel-Crafts plant with ~70% higher capacity is under construction, and management is actively evaluating greenfield and brownfield options, with capex likely not less than INR 100–150 crores once products are finalized.
• Customer concentration is a known risk being addressed: Management is "very clear" on reducing dependency on DuPont while acknowledging the relationship has been the foundation of growth since 2018; new geographies and products are the planned offset.
• What to watch next quarter: Whether the Friedel-Crafts plant operationalizes on schedule (August–October 2023), progress on new permissions, and any monetization signal on the Silox stake.

Demand & Revenue Visibility

• Nine-month strength, Q3 moderation: Revenue grew 32% YoY over nine months driven by steady demand and new product introductions, but Q3 FY23 growth over Q3 FY22 was only 5%, reflecting the lumpy nature of the business where volumes, product mix, and pricing all shift quarter-to-quarter.
• Demand visibility solid through year-end: Management sees good visibility until at least the end of this calendar year and does not expect any major drop or change in the current demand situation.
• International markets lead: Growth has been primarily driven by international business compared to domestic, with the company working on building presence in South America, Eurasia, and Japan, where it has positive indications.
• Quarterly comparisons are misleading: Volumes, product mix, pricing, and raw material costs all vary quarter-to-quarter, and the same product sold to the US versus Korea can carry different pricing and margin, making quarterly comparisons "not very appropriate" per management.

Bimal Mehta: "If you try to compare Transpek's performance from a quarter-to-quarter basis either in the same year or comparing to the previous years, it would not be very appropriate. Because see, the business is not such that every quarter we have specific allocation of the quantities or the volumes."

Capacity & Permissions: The Binding Constraint

• Permission-limited at Ekalbara: The existing site has reached its peak in terms of regulatory permissions; acid chloride output is capped at 250 MT/month maximum, and further expansion there requires new permissions.
• Friedel-Crafts plant adds ~100 MT/month: The new multi-product plant, designed with ~70% higher capacity than the one it replaces, will add approximately 1,200 MT/annum once operational, targeted between August and October 2023.
• Additional permission received but underutilized: An extra 450 MT/month permission was granted based on the company's ability to keep effluent and emission unchanged, but utilization is limited to ~200–250 MT/month under current constraints.
• Permission timelines are unpredictable: Regulatory approvals can take 3–4 months or stretch to 6–9 months depending on authority records, creating uncertainty in expansion planning.
• Land bank available if permissions open: Roughly 55–60 acres of the 100-acre Ekalbara parcel remain unused, providing room for additional capacity if the regulatory environment becomes more favorable beyond 2024.

Bimal Mehta: "Secondly, as I have mentioned earlier, that we have currently a limitation of permission. So we will have to work on that."

New Products & Pipeline

• Five products commercialized in 9M FY23: New introductions have already contributed to the 32% nine-month revenue growth, with two more products in the pipeline for launch.
• Deep development funnel: 15–17 products are at various stages of development targeting pharmaceuticals, polymers, and agrochemicals across multiple regions, with the company working with six-seven new potential customers in Japan, two-three in Korea, a couple in South America, and one or two in Eurasia.
• Not all products will commercialize: Management cautioned that product development carries inherent uncertainty: end-product demand or chemistry may change during the ~2-year development cycle, and some products reach a stage but are found not worth commercializing.
• Scaling path varies by product: Some of the 5–7 products being commercialized can be scaled to full extent with current permissions, while others have larger markets and will require a combination of job-work partners and expansion options to capture.

Bimal Mehta: "Many a times what happens is that the product is being developed and we reach to a stage, but then we find out that it's not worth to commercialize or even customers may say that their entire project has changed so it's not something that is always 100% sure..."

Customer Concentration & the DuPont Relationship

• DuPont dependency is acknowledged: Management is "very clear" they need to reduce product and customer dependency on DuPont, and is working on new products and entering new markets like South America, Japan, and Eurasia as the offset.
• But the relationship is foundational: The significant business from DuPont since 2018 has been the launch pad for the current growth phase, and management describes DuPont as an extremely reliable and trustworthy customer that consistently supports the company.
• No renewal discussion yet: There has been no specific discussion on contract renewal, but management understands the market for products DuPont makes from Transpek's supplies is "pretty solid" over coming years, and the relationship and service ability are proven.
• Margin resilience rests on customer trust: The ability to maintain respectable margins is attributed to very long-term customer relationships (some since the 1990s) where cost and price issues are resolved jointly, plus consistent batch-to-batch high-purity product quality and technical ability to handle hazardous chemicals at scale.

Bimal Mehta: "On the other hand, it is extremely difficult to find such a reliable and such a trustworthy customer, who is ready to consistently support you. and whatever growth that we are talking about in Transpek as of now and what now we are talking about this being the launch pad for the next phase of growth is also while it is we are dependent, but it is also because of the significant business that we got from DuPont since 2018."

Expansion Strategy: Greenfield, Brownfield & the Quantum Leap

• Greenfield on the drawing board: Management is actively evaluating all strategic possibilities for a greenfield project, which could be in Gujarat, Dahej, elsewhere, or even outside Gujarat, depending on products, customer geography, and overall strategy; the company is not waiting solely on Ekalbara permissions.
• Capex likely INR 100–150 crores: Once products are finalized, capex for the new plan will be "not less than INR 100 crores, INR 150 crores," but specifics depend on which products and volumes are finally chosen.
• Brownfield also in play: If the government opens up permissions in the current area, brownfield expansion at Ekalbara remains an option, and management is representing to government via trade associations to open up permissions.
• Philosophy: build base, then leap: Management's stated approach is balanced between aggressive and conservative: build a very solid base, then take a quantum jump, with growth described as "the only constant."
• Trigger is simply the need to grow: The trigger for expansion decisions is not a specific event but the imperative to grow in product profile, geographies, numbers, and profits.

Bimal Mehta: "We always believe in building a very strong base and then take a quantum leap. So now, after, as you mentioned, after 2018, we have built a very strong base and we will very soon be able to take quantum leap if markets and situations, so permit."

Costs, Margins & Other Financial Items

• Cost pressures easing: Freight charges and raw material prices have eased in the global market, helping reduce cost pressure in recent times, though supply-side disruptions and raw material availability issues are expected to continue in the near term.
• Q3 opex dropped sharply from Q2: Operating expenses fell from INR 52 cr in Q2 to INR 42 cr in Q3 because Q2 included ~INR 4.5 cr higher freight costs (since eased), an asset write-off of ~INR 2.4 cr not repeated, and a foreign exchange impact variance of ~INR 1.5 cr.
• Freight costs vary with geography mix: Freight costs fluctuate quarter-to-quarter because of both absolute freight rate changes and geographic mix shifts: more Korea vs US business lowers freight, while more US vs Korea raises it.
• Other income boosted by one-time items: 9M FY23 other income was significantly higher because of a special dividend from Transpek Silox and a small insurance claim received.
• Net block rose on capex capitalization: Net block increased ~INR 60 cr between March and September 2022 because of capitalization of prior-year capital work-in-progress carried forward, plus current-year capex.
• Depreciation covers maintenance capex: Depreciation "largely takes care of" replacement of equipment and plant assets, with no significant mismatch, aided by anti-corrosion practices that manage the corrosive nature of products.
• Silox stake is illiquid, not on near-term horizon: The investment in Transpek Silox carries agreement clauses giving Silox preference to buy; management said "at right time we may be able to monetise this, but right now it's not something that is on our horizon."

Guidance & Commitments

Key Metrics